摘要
目的探讨选择性环氧合酶-2抑制剂与顺铂联合应用产生协同的抗卵巢癌作用。方法利用移植卵巢癌细胞株小鼠模型,研究环氧合酶-2抑制剂美洛昔康联合顺铂对小鼠生存期限、肿瘤生长以及小鼠体内前列腺素E2(prostaglandin E2,PGE2)水平、VEGF表达的影响。结果单独使用顺铂或美洛昔康均可延长DISS腹水小鼠的生存时间、抑制OVCAR-3肿瘤细胞的生长(P<0.01),并可降低恶性腹水小鼠的腹水及转移瘤小鼠血清中的PGE2水平(P<0.01),降低转移肿瘤组织中VEGF的表达(P<0.01)。联合用药与单独使用顺铂或美洛昔康比较,明显增加对实验小鼠的抑制肿瘤效果。结论美洛昔康与顺铂联合使用对卵巢肿瘤的生长抑制有协同增效的作用。
Objective To investigate the effects of combination of meloxicam, a selective COX-2 inhibitor, with cisplatin （CDDP） on the growth of human epithelial ovarian cancer （EOC） in nude mice. Methods Female nu/nu mice xenografted with subcutaneous OVCAR-3 cells or with intraperitoneal DISS cells were treated with cisplation alone, meloxicam alone or the combination. The effect of these treatments on survival time, tumor growth, prostaglandin E2 level and the expression of VEGF was evaluated. Results Meloxicam alone, CDDP alone or combination of meloxicam with CDDP significantly suppressed the growth of OVCAR-3 tumors xenografted subcutaneously and prolonged the survival of mice with malignant ascites derived from DISS cells compared to control（ P 〈0. 01 ）. PGE2 and VEGF levels in serum and in ascites were decreased significantly （P 〈 0. 01 ）. Furthermore, the combination of meloxicam with CDDP produced a significantly greater antitumor effect than CDDP or meloxicam alone（ P 〈 0. 01 ）. Conclusion Combination of meloxicam with cisplatin produces an additive antitumor activity against human ovarian cancer in nude mice,indicating that it may lead to a novel therapeutic strategy for ovarian cancer.
出处
《实用肿瘤杂志》
CAS
2014年第1期83-87,共5页
Journal of Practical Oncology
关键词
卵巢肿瘤
药物疗法
卵巢肿瘤
病理学
环氧化酶2抑制剂
治疗应用
顺铂
治疗应用
药物疗法
联合
血管内皮生长因子A
药物作用
药物协同作用
疾病模型
动物
ovarian neoplasms/drug therapy
ovarian neoplasms/pathology
cyclooxygenase 2 inhibitors/therapeutie use
cisplatin/therapeutic use
drug therapy, combination
vascular endothelial growth factor A/drug effects
drug synergism
disease models, animal
